在药物开发中, δ-阿片类受体作为增加心脏对再输液抵抗的分子标
Natalia V Naryzhnaya1, Alexander V Mukhomedzyanov1, Maria Sirotina1
1Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk 634021, Russia.
Biomedicines
|July 29, 2023
概括
周围的delta-2阿片类受体 (δ2-OR) 的激活可以提高心脏对再注血的耐受性. 这种心脏保护作用涉及蛋白激酶和离子通道,为心脏病提供潜在的治疗策略.
科学领域:
- 心血管生理学心血管生理学
- 分子心脏病学分子心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 重灌损伤仍然是心血管医学的一个重大挑战.
- 阿片类受体在心脏保护中的作用是正在进行的研究领域.
- 外周阿片类受体,特别是δ2-阿片类受体 (δ2-OR),已涉及到调节心脏功能.
研究的目的:
- 调查外围 δ2-阿片类受体 (δ2-OR) 在心脏对再注射的耐受性中的作用.
- 阐明参与δ2-OR激活心脏保护作用的信号通路和分子点.
主要方法:
- 分析已发表的数据和原始实验研究.
- 在δ2-OR激活后评估心脏对再注血的耐受性.
- 研究蛋白激酶激活 (PKCδ,ERK1/2,PI3K,PKG) 和效应器通路 (KATP通道,MPT孔).
主要成果:
- 外周 δ2-阿片类受体 (δ2-OR) 的激活显著增加了心脏对再注血的耐受性.
- δ2-ORs位于心肌细胞内,这表明它在心脏保护中发挥着直接作用.
- 德尔托芬II δ2-OR 主激素的心脏病限制作用是由特定蛋白质激酶的激活介导的.
- 潜在的下游影响者包括sarcolemmal KATP通道和线粒体透性过渡孔 (MPTP).
结论:
- 外周 δ2-阿片类受体 (δ2-OR) 的激活使心脏受到反损伤的保护.
- 该机制涉及一连串的蛋白质激酶,可能针对离子通道和线粒体孔.
- 内源性阿片类药物似乎无法调节心脏对再注射的抵抗力.
相关概念视频
Opioid Receptors: Overview
1.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Analgesia and Pain Management
660
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
660
Heart Failure Drugs: Inotropic Agents
625
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
625
Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
Drug-Receptor Interaction: Antagonist
3.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
3.1K


